These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 19732860)

  • 1. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase.
    Tsai C; Caillet C; Hu H; Zhou F; Ding H; Zhang G; Zhou B; Wang S; Lu S; Buchy P; Deubel V; Vogel FR; Zhou P
    Vaccine; 2009 Nov; 27(48):6777-90. PubMed ID: 19732860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus.
    Ding H; Tsai C; Zhou F; Buchy P; Deubel V; Zhou P
    PLoS One; 2011 Mar; 6(3):e17821. PubMed ID: 21464977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies.
    Temperton NJ; Hoschler K; Major D; Nicolson C; Manvell R; Hien VM; Ha do Q; de Jong M; Zambon M; Takeuchi Y; Weiss RA
    Influenza Other Respir Viruses; 2007 May; 1(3):105-12. PubMed ID: 19453415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy of a pre-pandemic H5N1 vaccine (MG1109) in mouse and ferret models.
    Song MS; Moon HJ; Kwon HI; Pascua PN; Lee JH; Baek YH; Woo GJ; Choi J; Lee S; Yoo H; Oh I; Yoon Y; Rho JB; Sung MH; Hong SP; Kim CJ; Choi YK
    J Microbiol; 2012 Jun; 50(3):478-88. PubMed ID: 22752912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.
    Smith GE; Sun X; Bai Y; Liu YV; Massare MJ; Pearce MB; Belser JA; Maines TR; Creager HM; Glenn GM; Flyer D; Pushko P; Levine MZ; Tumpey TM
    Virology; 2017 Sep; 509():90-97. PubMed ID: 28624679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses.
    Zhou F; Wang G; Buchy P; Cai Z; Chen H; Chen Z; Cheng G; Wan XF; Deubel V; Zhou P
    J Virol; 2012 Jun; 86(12):6970-8. PubMed ID: 22496212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays.
    Wang W; Xie H; Ye Z; Vassell R; Weiss CD
    J Virol Methods; 2010 May; 165(2):305-10. PubMed ID: 20153374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
    Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.
    Changsom D; Lerdsamran H; Wiriyarat W; Chakritbudsabong W; Siridechadilok B; Prasertsopon J; Noisumdaeng P; Masamae W; Puthavathana P
    PLoS One; 2016; 11(4):e0153183. PubMed ID: 27054879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.
    Khurana S; Wu J; Verma N; Verma S; Raghunandan R; Manischewitz J; King LR; Kpamegan E; Pincus S; Smith G; Glenn G; Golding H
    J Virol; 2011 Nov; 85(21):10945-54. PubMed ID: 21865396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge.
    Kingstad-Bakke B; Kamlangdee A; Osorio JE
    Vaccine; 2015 Sep; 33(39):5155-62. PubMed ID: 26271828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA prime and virus-like particle boost from a single H5N1 strain elicits broadly neutralizing antibody responses against head region of H5 hemagglutinin.
    Wang G; Zhou F; Buchy P; Zuo T; Hu H; Liu J; Song Y; Ding H; Tsai C; Chen Z; Zhang L; Deubel V; Zhou P
    J Infect Dis; 2014 Mar; 209(5):676-85. PubMed ID: 23911711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
    Zhu H; Ding X; Chen X; Yao P; Xu F; Xie R; Yang Z; Liang W; Zhang Y; Li Y; Shen J; He P; Guo Z; Su B; Sun S; Zhu Z
    Vaccine; 2011 Jul; 29(33):5421-3. PubMed ID: 21645575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans.
    Nachbagauer R; Wohlbold TJ; Hirsh A; Hai R; Sjursen H; Palese P; Cox RJ; Krammer F
    J Virol; 2014 Nov; 88(22):13260-8. PubMed ID: 25210189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
    Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
    Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.